bioAffinity Technologies, Inc. announced on June 24, 2025, that it received notification of a patent grant from the China National Intellectual Property Administration. This patent covers the company's novel method of using small interfering RNAs (siRNAs) to selectively kill cancer cells.
This patent grant is a significant expansion of bioAffinity Technologies' intellectual property portfolio into China, a major global market. China has over 300 million smokers and an estimated 1.06 million new lung cancer cases diagnosed in 2022, representing a substantial market for cancer therapies.
The patent strengthens the global commercialization potential for the company's therapeutic discoveries, which target specific cell surface receptors (CD320 and LRP2) to selectively eliminate cancer cells while sparing normal cells. This development supports the company's strategy to build long-term shareholder value through innovation and protection of its unique assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.